TransMedics Group Inc vs Exxon Mobil Corporation — how do they compare? TransMedics Group Inc trades at $77.5 (market cap $2.74B), while Exxon Mobil Corporation trades at $168.76 (market cap $692.86B). The key difference: Exxon Mobil Corporation is far larger — about 252.9× TransMedics Group Inc's market cap, and Exxon Mobil Corporation pays a 2.45% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Exxon Mobil Corporation for 99 Days on average.
| TMDX | XOM | |
|---|---|---|
Market Cap | $2.74B | $692.86B |
Volume | 949,331 | 13,225,996 |
Sector | Health | Energy |
52-Week High | $150.42 | $171.52 |
52-Week Low | $61.99 | $110.64 |
Typical Hold Time | 24 Days | 99 Days |
Enterprise Value | $3.13B | $724.64B |
Dividend Yield | — | 2.45% |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Exxon Mobil (XOM) trades at $164.06, down 0.26% on the day, with a bullish technical signal and strong support at $163. The company reported mixed Q2 2026 earnings, missing EPS estimates, but maintains solid profitability with a 9.07% net margin. Recent news highlights potential expansion into Venezuela's oil fields and ongoing growth in Guyana and Permian Basin assets. Cash flow from operations remains robust at $52.0 billion in 2025, though net cash flow was negative due to high capital expenditures.
XOM offers a stable dividend and growth potential from strategic investments, but faces risks from volatile oil prices and geopolitical exposure. Analyst consensus is a 'Hold' with a $169.45 price target, indicating modest upside. Revenue declines from 2022-2025 pose a concern, but projected 2026 growth to $361.1 billion may reverse the trend. The stock's valuation ratios, including a P/E of 21.69, are reasonable for the energy sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →